title: Utilization of the coronary balloon-expandable coil stent without anticoagulation or intravascular ultrasound.
abstract: BACKGROUND
  The balloon-expandable coil stent has been proved effective in the management of acute and threatened closure after coronary balloon angioplasty and has been shown to reduce restenosis in patients with suboptimal results after coronary balloon angioplasty. Coronary artery stenting has been limited by the occurrence of stent thrombosis and comorbidity related to anticoagulation. This study was undertaken to determine whether anticoagulation may be removed from poststenting protocols, thus reducing comorbidity without increasing stent thrombosis.
  
  
  RESULTS
  Between September 1994 and May 1995, 369 patients received balloon-expandable coil stents in native coronary arteries at our institution. Of these patients, 216 were selected for a protocol of aspirin and ticlopidine (for 1 month) without anticoagulation. Eligibility for this protocol followed satisfaction of certain procedural and angiographic criteria. These criteria included adequate coverage of intimal dissections, absence of residual filling defects, and normal (TIMI grade 3) flow in the stented vessel after high-pressure balloon inflations. Intravascular ultrasound was not used to guide stent deployment. The stenting procedure was planned in 37% of patients and unplanned in 63% of patients, including 25 (12%) for acute or threatened closure. During the 30-day follow-up period, stent thrombosis occurred in 2 patients (0.9%), there was 1 death (0.5%), and 2 patients (0.9%) underwent coronary bypass surgery. Vascular access-site complications occurred in 4 patients (1.9%), and bleeding that required blood transfusion occurred in 4 patients (1.9%).
  
  
  CONCLUSIONS
  Patients who receive the coronary balloon-expandable coil stent with optimal angiographic results without intravascular ultrasound guidance can be managed safely with a combination of aspirin and ticlopidine without anticoagulation.
authors.affiliation: Division of Cardiovascular Diseases, University of Alabama at Birmingham, 35294, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Goods
authors.forename: K F
authors.initials: KF
authors.lastname: Al-Shaibi
authors.forename: S S
authors.initials: SS
authors.lastname: Yadav
authors.forename: M W
authors.initials: MW
authors.lastname: Liu
authors.forename: B H
authors.initials: BH
authors.lastname: Negus
authors.forename: S S
authors.initials: SS
authors.lastname: Iyer
authors.forename: L S
authors.initials: LS
authors.lastname: Dean
authors.forename: S P
authors.initials: SP
authors.lastname: Jain
authors.forename: W A
authors.initials: WA
authors.lastname: Baxley
authors.forename: J M
authors.initials: JM
authors.lastname: Parks
authors.forename: R J
authors.initials: RJ
authors.lastname: Sutor
authors.forename: G S
authors.initials: GS
authors.lastname: Roubin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000925:Anticoagulants / Q000627:therapeutic use; D017023:Coronary Angiography; D003331:Coronary Vessels / Q000000981:diagnostic imaging; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015607:Stents / Q000009:adverse effects; D013988:Ticlopidine / Q000009:adverse effects / Q000627:therapeutic use; D014463:Ultrasonography
chemical_list: D000925:Anticoagulants; D013988:Ticlopidine